Effects of rituximab and dexamethasone on regulatory and proinflammatory B‐cell subsets in patients with primary immune thrombocytopenia

Abstract

Both treatment regimens normalized the frequencies of cytokine-producing B cells. The additional increase in CD5⁺ B cells after RTX+DXM is compatible with induction of Bregs.